Cargando…
Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial
INTRODUCTION: The α-glucosidase inhibitor acarbose is an efficacious medicine for the treatment and prevention of type 2 diabetes mellitus (T2DM). However, the response of gut microbiota to acarbose is important, as the microbiota may have a critical role in the development of metabolic diseases, an...
Autores principales: | Zhang, Xiuying, Fang, Zhiwei, Zhang, Chunfang, Xia, Huihua, Jie, Zhuye, Han, Xueyao, Chen, Yingli, Ji, Linong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380489/ https://www.ncbi.nlm.nih.gov/pubmed/28130771 http://dx.doi.org/10.1007/s13300-017-0226-y |
Ejemplares similares
-
Human Gut Microbiota Changes Reveal the Progression of Glucose Intolerance
por: Zhang, Xiuying, et al.
Publicado: (2013) -
Extension of the Life Span by Acarbose: Is It Mediated by the Gut Microbiota?
por: Wu, Baiyun, et al.
Publicado: (2022) -
Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats
por: Zhang, Minchun, et al.
Publicado: (2019) -
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
por: Hanefeld, Markolf
Publicado: (2007) -
Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
por: Ueno, Hiroaki, et al.
Publicado: (2015)